替吉奥单药治疗晚期乳腺癌疗效及安全性观察

Observation on efficacy and safety of tegafur monotherapy in the treatment of advanced breast cancer

目的观察替吉奥单药治疗晚期乳腺癌的疗效及安全性。方法 82例晚期乳腺癌患者,采用数字表随机法分为观察组和对照组,各41例。观察组给予替吉奥单药治疗,对照组给予卡培他滨单药治疗,均于治疗2个周期后评价两组临床疗效,记录两组用药期间毒副反应。结果观察组缓解率(RR)为31.71%,对照组RR为34.15%,两组比较差异无统计学意义(P>0.05)。两组骨髓抑制、血小板减少、贫血、腹泻、口角炎、肝损害反应发生率及反应程度比较差异无统计学意义(P>0.05)。观察组恶心呕吐Ⅰ~Ⅱ发生率为26.83%,Ⅲ~Ⅳ发生率为0,手足综合征Ⅰ~Ⅱ发生率为4.88%,Ⅲ~Ⅳ发生率为0;对照组恶心呕吐Ⅰ~Ⅱ发生率为48.78%,Ⅲ~Ⅳ发生率为0,手足综合征Ⅰ~Ⅱ发生率为46.34%,Ⅲ~Ⅳ发生率为9.76%;观察组恶心呕吐、手足综合征发生率明显低于对照组,差异有统计学意义(P<0.05)。结论替吉奥疗效确切,服用方便、毒副反应易耐受,而且适合门诊治疗,因此初步认为替吉奥单药是晚期乳腺癌患者较合理的治疗方案,值得推广应用。

Objective To observe the efficacy and safety of tegafur monotherapy in the treatment of advanced breast cancer.Methods A total of82advanced breast cancer patients were divided by random number table method into observation group and control group,with41cases in each group.The observation group was treated with tegafur monotherapy,and the control group was treated with capecitabine monotherapy.After two cycles of treatment,the clinical efficacy of the two groups was evaluated,and the toxic and side effects between the two groups were recorded.Results The observation group had remission rate(RR)as31.71%,which was31.71%in the control group,and their difference was not statistically significant(P>0.05).Both groups had no statistically significant difference in bone marrow suppression,thrombocytopenia,anemia,diarrhea,angular cheilitis,liver damage reaction rate and reaction degree(P>0.05).The observation group had incidence of nausea and vomiting inⅠ~Ⅱdegree as26.83%,Ⅲ~Ⅳdegree as0,and incidence of hand and foot syndrome inⅠ~Ⅱdegree as4.88%,Ⅲ~Ⅳdegree as0,which were48.78%,0,46.34%and9.76%in the control group.The observation group had obviously lower incidence of nausea and vomiting and hand and foot syndrome than the control group,and the difference was statistically significant(P<0.05).Conclusion Tegafur shows affirmative efficacy,and is easy to take,and its side effects is easy to tolerate.It is suitable for outpatient treatment.So tegafur monotherapy is more reasonable for patients with advanced breast cancer,and it is worthy of popularization and application.